A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival
Publication
, Conference
Chawla, S; Van Tine, BA; Pollack, S; Ganjoo, K; Elias, A; Riedel, RF; Attia, S; Choy, E; Okuno, S; Agulnik, M; von Mehren, M; Livingston, M ...
Published in: ANNALS OF ONCOLOGY
September 1, 2017
Duke Scholars
Published In
ANNALS OF ONCOLOGY
EISSN
1569-8041
ISSN
0923-7534
Publication Date
September 1, 2017
Volume
28
Location
Madrid, SPAIN
Publisher
OXFORD UNIV PRESS
Conference Name
42nd European-Society-for-Medical-Oncology Congress (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Chawla, S., Van Tine, B. A., Pollack, S., Ganjoo, K., Elias, A., Riedel, R. F., … Maki, R. (2017). A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival. In ANNALS OF ONCOLOGY (Vol. 28). Madrid, SPAIN: OXFORD UNIV PRESS.
Chawla, S., B. A. Van Tine, S. Pollack, K. Ganjoo, A. Elias, R. F. Riedel, S. Attia, et al. “A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival.” In ANNALS OF ONCOLOGY, Vol. 28. OXFORD UNIV PRESS, 2017.
Chawla S, Van Tine BA, Pollack S, Ganjoo K, Elias A, Riedel RF, et al. A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival. In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2017.
Chawla, S., et al. “A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival.” ANNALS OF ONCOLOGY, vol. 28, OXFORD UNIV PRESS, 2017.
Chawla S, Van Tine BA, Pollack S, Ganjoo K, Elias A, Riedel RF, Attia S, Choy E, Okuno S, Agulnik M, von Mehren M, Livingston M, Keedy V, Verschraegen C, Philip T, Bohac C, Lu H, Chen M, Maki R. A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2017.
Published In
ANNALS OF ONCOLOGY
EISSN
1569-8041
ISSN
0923-7534
Publication Date
September 1, 2017
Volume
28
Location
Madrid, SPAIN
Publisher
OXFORD UNIV PRESS
Conference Name
42nd European-Society-for-Medical-Oncology Congress (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis